-
Product Insights
NewPsychosis – Drugs In Development, 2024
Empower your strategies with our Psychosis – Drugs In Development, 2024 report and make more profitable business decisions. Psychosis is a condition that affects the mind and causes a loss of contact with reality. People with psychosis may experience hallucinations (seeing or hearing things that are not there) and delusions (believing things that are not true). Psychosis can be a symptom of various mental disorders, such as schizophrenia, bipolar disorder, or severe depression. It can also be triggered by stress, trauma,...
-
Product Insights
NewMultiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) – Drugs In Development, 2024
Empower your strategies with our Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) – Drugs In Development, 2024 report and make more profitable business decisions. Multiple system atrophy (MSA), or Shy-Drager syndrome, is a neurological disorder that impairs the body's involuntary functions (blood pressure, heart rate, bladder function, and digestion). Symptoms include rigid muscles, bradykinesia, tremors, dysarthria, dysphagia, constipation, incontinence, and irregular heartbeat. Treatment is aimed at relieving symptoms with anti-Parkinson's medications. The Multiple System Atrophy (MSA or Shy-Drager...
-
Product Insights
NewAutism Spectrum Disorder (ASD) – Drugs In Development, 2024
Empower your strategies with our Autism Spectrum Disorder (ASD) – Drugs In Development, 2024 report and make more profitable business decisions. Autism Spectrum Disorder (ASD) is a neurodevelopmental condition characterized by challenges in social interaction, communication, and repetitive behaviors. Symptoms range from mild to severe, forming a spectrum. Individuals with ASD may have difficulties in understanding social cues, expressing emotions, and engaging in reciprocal conversations. Sensory sensitivities are common, affecting responses to stimuli. Early intervention and tailored support can enhance communication...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ENT-03 in Obesity
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ENT-03 in Obesity report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ENT-03 in Obesity Drug Details: ENT-03 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ENT-03 in Type 2 Diabetes
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ENT-03 in Type 2 Diabetes report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ENT-03 in Type 2 Diabetes Drug Details: ENT-03 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ENT-01 in Constipation
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ENT-01 in Constipation report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ENT-01 in Constipation Drug Details: ENT-01 is under development for the treatment...
-
Product Insights
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Alpha Synuclein (SNCA) Drugs in Development Report Overview Alpha-synuclein is a protein normally found in cells all over the body and is one of the key players in Parkinson’s disease. The Alpha Synuclein (Non A Beta Component of AD Amyloid or Non A4 Component of Amyloid Precursor or NACP or SNCA) drugs in development research report provides comprehensive information on the therapeutics under development for Alpha Synuclein. The report also analyzes the stage of development, mechanism of action (MoA), route...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ENT-01
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry ENT-01 Drug Details ENT-01 is under development for the treatment of dementia associated with...
-
Product Insights
Dementia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Dementia is the loss of mental functions such as thinking, memory, and reasoning that is severe enough to interfere with a person's daily functioning. Symptoms include memory loss, hallucinations, agitation, personality changes, and difficulty with coordination and motor functions. Risk factors include age, smoking, obesity, high blood pressure, inflammation, and cardiovascular diseases. The Dementia Drugs in Development market research report provides an overview of the Dementia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dementia,...